BUNNAGE MARK E. (EVP, Chief Scientific Officer) sold 29.9% of their position (3.62K shares) of VERTEX PHARMACEUTICALS INC / MA on the open market
Open‑market sale worth $1.75M — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 2/19/2026ACC: 0000875320-26-000088
Officer· EVP, Chief Scientific Officer
Since Feb 2026
-2.15K
Net shares
Net seller
$2.29M
Total sold
2
Open market trades
0B · 2S
4
Total transactions
2.58K acquired · 4.73K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
+2.58K
Price / share
—
Trade value
—
% of position
24.3%
2/17/2026
10.63K→13.21K
Common Stock
Direct
Shares
−1.11K
Price / share
$483.75
Trade value
$536.96K
% of position
8.4%
2/17/2026
13.21K→12.11K
Common Stock
Direct
Shares
−2.44K
Price / share
$489.46
Trade value
$1.19M
% of position
20.1%
2/17/2026
12.11K→9.67K
Common Stock
Direct
Shares
−1.18K
Price / share
$473.68
Trade value
$559.89K
% of position
12.2%
2/18/2026
9.67K→8.49K
Total
Net shares
−2.15K
Net value
-$2.29M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/17/2026 | A · Award | +2.58K | — | — | 24.3% | 10.63K | 13.21K |
| Common Stock Direct | 2/17/2026 | F · Tax Withholding | −1.11K | $483.75 | $536.96K | 8.4% | 13.21K | 12.11K |
| Common Stock Direct | 2/17/2026 | S · Sale | −2.44K | $489.46 | $1.19M | 20.1% | 12.11K | 9.67K |
| Common Stock Direct | 2/18/2026 | S · Sale | −1.18K | $473.68 | $559.89K | 12.2% | 9.67K | 8.49K |
| Total | −2.15K | -$2.29M | ||||||
Derivative Transactions0
No derivative transactions reported